Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

by Fengzhi Li, Ieman Aljahdali, Xiang Ling
Published 2019-08-01

A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

by Xiang Ling, Shousong Cao, Qiuying Cheng, James T Keefe, Youcef M Rustum, Fengzhi Li
Published 2012-01-01

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

by Fengzhi Li, Ieman A. M. Aljahdali, Renyuan Zhang, Kent L. Nastiuk, John J. Krolewski, Xiang Ling
Published 2021-08-01

An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer

by Xiang Ling, Wenjie Wu, Chuandong Fan, Chao Xu, Jianqun Liao, Laurie J. Rich, Ruea-Yea Huang, Elizabeth A. Repasky, Xinjiang Wang, Fengzhi Li
Published 2018-10-01

Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder C...

by Sreevidya Santha, Xiang Ling, Ieman A. M. Aljahdali, Sailee S. Rasam, Xue Wang, Jianqun Liao, Jue Wang, Christos Fountzilas, Qingyong Li, Jun Qu, Fengzhi Li
Published 2020-11-01

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant

by Lisa C. Holthof, Arwen Stikvoort, Hilma J. van der Horst, Anne T. Gelderloos, Renée Poels, Fengzhi Li, Richard W. J. Groen, Sonja Zweegman, Niels W. C. J. van de Donk, Michael O’Dwyer, Tuna Mutis
Published 2021-05-01